Printer Friendly

ISOMEDIX REPORTS SECOND QUARTER RESULTS

 WHIPPANY, N.J., July 26 /PRNewswire/ -- Isomedix inc. (NASDAQ: ISMX) today reported a 15 percent increase in second quarter consolidated sales to a record $10,805,461 compared with sales of $9,380,946 for the same period in 1992. Operating income increased 14 percent to $3,223,475 compared to $2,836,927 for the 992 period. The company noted that the 1992 period included a non-recurring expense of approximately $268,000 resulting from the prepayment of an industrial development revenue bond.
 Consolidated net income in the second quarter was $1,950,077 compared with $2,022,495 earned a year ago. This slight decrease of $72,418 in net income is principally attributable to non-recurring interest income of approximately $370,000 ($229,400 after tax) received in 1992 on a tax refund and, as previously announced, to unexpected customer delays in utilizing the company's new ethylene oxide gas sterilization facility in Northborough, Mass. and its new gamma radiation facility in Chester, N.Y. Based on a weighted averaged number of 7,334,899 common shares outstanding in the second quarter compared with 7,109,557 shares a year ago, earnings per share were 27 cents for the second quarter compared with 28 cents for the same period last year.
 Consolidated sales for the six months ended June 30, 1993, increased 14 percent to $20,378,118 compared with $17,858,858 for the same period in 1992. Operating income increased 11 percent to $5,872,007 compared to $5,279,157 for the 1992 period. As noted above, the 1992 period included a non-recurring expense of approximately $268,000 resulting from the prepayment of an industrial development revenue bond.
 Consolidated net income for the six months ended June 30, 1993 increased 2 percent to $3,619,921 compared with $3,542,199 earned a year ago. This relatively flat increase in net income is principally attributable to customer delays in utilizing the company's new Northborough and Chester facilities, and to non-recurring interest income received in 1992 on a tax refund as described above. Based on a weighted average of 7,351,745 common shares outstanding in 1993 compared with 7,120,958 shares a year ago, earnings per share were 49 cents compared with 50 cents for the same period last year.
 Isomedix inc. operates a network of 10 sterilization facilities in eight states and Canada. The capability to sterilize medical devices with pure ethylene oxide has been added at three of the gamma facilities. The company also provides validation services through its Skyland Scientific Services subsidiary located in Montana.
 ISOMEDIX INC.
 Comparative Tables
 (Unaudited)
 Periods ended Three Months Six Months
 June 30 1993 1992 1993 1992
 Sales $10,805,461 $9,380,946 $20,378,118 $17,858,858
 Operating income 3,223,475 2,836,927 5,872,007 5,279,157
 Net income 1,950,077 2,022,495 3,619,921 3,542,199
 Earnings per share $0.27 $0.28 $0.49 $0.50
 Weighted average
 number of shares
 outstanding 7,334,899 7,109,557 7,351,745 7,120,958
 -0- 7/26/93
 /CONTACT: Thomas J. DeAngelo, vice president - finance and administration of Isomedix, 201-887-4700/
 (ISMX)


CO: Isomedix Inc. ST: New Jersey IN: MTC SU: ERN

MP-SM -- NY039 -- 5657 07/26/93 11:35 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 26, 1993
Words:555
Previous Article:UNIVERSAL SEISMIC ASSOCIATES, INC. ANTICIPATES LOSS FOR QUARTER ENDED JUNE 30, 1993
Next Article:STEWART INFORMATION SERVICES CORPORATION DOUBLES EARNINGS
Topics:


Related Articles
ISOMEDIX REPORTS RECORD FOURTH QUARTER AND RECORD YEAR END RESULTS; NET INCOME INCREASES 55 PERCENT
ISOMEDIX INC. ANNOUNCES SHARE REPURCHASE PROGRAM
ISOMEDIX REPORTS RECORD SALES FOR THE THIRD QUARTER
ISOMEDIX REPORTS RECORD SALES FOR THE FOURTH QUARTER
STERIS Reports Record Fiscal Second Quarter Results
STERIS Reports Record Fiscal Fourth Quarter and Full Year Results
Endocare Reports Second Quarter 1998 Financial Results Revenues Up 160% Over Second Quarter 1997
STERIS Corporation Announces Fiscal 2004 Second Quarter Results; Earnings Increase 11% To $0.29 Per Diluted Share; Earnings Outlook For The Year...
STERIS Corporation Announces Fiscal 2004 First Quarter Results; Earnings increase 28% to $0.23 per diluted share.
STERIS Corporation Announces Fiscal 2005 Second Quarter Results.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters